[1] HAIDER M,MEMON S,TARIQ F,et al.Rhesus isoimmunization: late-onset hemolytic disease of the newborn without jaundice[J].Cureus,2020,12(1): e6559. [2] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia.Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J].Pediatrics,2004,114(1):297-316. [3] 张钰,张璐,许纪玲,等.1300例新生儿溶血病血型血清学检测结果分析[J].中国输血杂志,2020,33(9):922-924. [4] 杜肖刚,王丽荣,段燕军.未孕女性IgG类抗A(B)抗体效价测定分析[J].长治医学院学报,2016,30(2):137-139. [5] 周明,王慧茹,陈洋,等.孕产妇Rh血型系统抗体检测和临床意义分析[J].安徽医药,2020,24(2):252-256. [6] YAMAMOTO F,CID E,YAMAMOTO M,et al.An integrative evolution theory of histo-blood group ABO and related genes[J].Sci Rep,2014,4:6601. [7] CAI X, JIN S, LIU X,et al.Molecular genetic analysis of ABO blood group variations reveals 29 novel ABO subgroup alleles[J]. Transfusion, 2013. 53(11 Suppl 2):2910-2916. [8] YING Y,HONG X,XU X,et al.Serological characteristic and molecular basis of A2 subgroup in the Chinese population[J].Transfus Apher Sci,2013,48(1):67-74. [9] WESTHOFF C M.The structure and function of the Rh antigen complex[J].Semin Hematol,2007,44(1):42-50. [10] FLEGEL W A,DENOMME G A,QUEENAN J T,et al.It's time to phase out“serologic weak D phenotype”and resolve D types with RHD genotyping including weak D type 4[J].Transfusion,2020,60(4):855-859. [11] TAN J C,ARMSTRONG N J,YUAN F F,et al.Identificat ion of genetic polymorphisms that predict responder/non-responder profiles to the RhD antigen[J].Mol Immunol,2015,68(2 pt c):628-633. [12] VILLALBA A,SANTIAGO M,FREIRIA C,et al.Anti-D alloimmunization after RhD-positive platelet transfusion in RhD-negative women under 55 years diagnosed with acute leukemia: results of a retrospective study[J].Transfus Med Hemother,2018,45(3):162-166. [13] ARTHUR C M,PATEL S R,SMITH N H,et al.Antigen density dictates immune responsiveness following red blood cell transfusion[J].J Immunol,2017,198(7): 2671-2680. [14] KWON D H,SANDLER S G,FLEGEL W A.DEL phenotype[J].Immunohematology,2019,33(3):125-132. [15] SCHONEWILLE H,DOXIADIS I I,LEVERING W H,et al.HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies[J].Transfusion,2014,54(8):1971-1980. [16] VERDUIN E P,BRAND A,VAN DE WATERING L M G,et al.The HLA-DRB1*15 phenotype is associated with multiple red blood cell and HLA antibody responsiveness[J].Transfusion,2016,56(7):1849-1856. [17] BAO W,ZHONG H,LI X,et al.Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major[J].Am J Hematol,2011,86(12): 1001-1006. [18] PAL M,BAO W,WANG R,et al.Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease[J].Blood,2021,137(2):269-280. [19] KING C,TANGYE S G,MACKAY C R.T follicular helper (TFH) cells in normal and dysregulated immune responses[J].Annu Rev Immunol,2008,26(1): 741-766. [20] MCGUIRE H M,VOGELZANG A,WARREN J,et al.IL-21 and IL-4 collaborate to shape T-dependent antibody responses[J].J Immunol,2015,195(11): 5123-5135. [21] BÉLANGER S,CROTTY S.Dances with cytokines,featur ing T_FH cells,IL-21,IL-4 and B cells[J].Nat Immunol,2016,17(10):1135-1136. [22] GODEFROY E,ZHONG H,PHAM P,et al.TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization[J].Haematologica,2015,100(11):1415-1425. [23] NATARAJAN P,LIU D,PATEL S R,et al.CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model[J].Front Immunol,2017,8:907. [24] GIBB D R,LIU J C,NATARAJAN P,et al.Type I IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice[J].J Immunol,2017,199(3):1041-1050. [25] MENER A,PATEL S R,ARTHUR C M,et al.Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses[J].JCI Insight,2018,3(22):e121631. [26] CALABRO S,GALLMAN A,GOWTHAMAN U,et al.Bridging channel dendritic cells induce immunity to transfused red blood cells[J].J Exp Med,2016,213(6): 887-896. [27] ARNEJA A,SALAZAR J E,JIANG W,et al.Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization[J].Haematologica,2016,101(11): e440-e444. [28] FASANO R M,BOOTH G S,MILES M,et al.Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease[J].Br J Haematol,2015,168(2): 291-300. [29] PAPAY P,HACKNER K,VOGELSANG H,et al.High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease[J].Am J Med,2012,125(7):717.e1-717.e8. [30] HANCHARD N A,MOULDS J M,BELMONT J W,et al.A genome-wide screen for large-effect alloimmunization susceptibility loci among red blood cell transfusion recipients with sickle cell disease[J].Transfus Med Hemother,2014,41(6):453-461. [31] SIMMONS D P,SAVAGE W J.Hemolysis from ABO incompatibility[J].Hematol Oncol Clin North Am,2015,29(3):429-443. [32] BERENTSEN S,SUNDIC T.Red blood cell destruction in autoimmune hemolytic Anemia: role of complement and potential new targets for therapy[J].Biomed Res Int,2015,2015:1-11. [33] EINARSDOTTIR H K,STAPLETON N M,SCHERJON S,et al.On the perplexingly low rate of transport of IgG2 across the human placenta[J].PLoS One,2014,9(9):e108319. [34] VIDARSSON G,DEKKERS G,RISPENS T.IgG subclasses and allotypes: from structure to effector functions[J].Front Immunol,2014,5:520. [35] 马印图,王更银,李烛,等.母婴血型不合新生儿溶血病IgG抗体亚型分析[J].临床输血与检验,2020,22(3): 269-272. [36] KUMPEL B M,SALDOVA R,KOELEMAN C A M,et al.Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy[J].Sci Rep,2020,10(1):1464. [37] KAPUR R,DELLA VALLE L,SONNEVELD M,et al.Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn[J].Br J Haematol,2014,166(6):936-945. [38] SONNEVELD M E,KOELEWIJN J,DE HAAS M,et al.Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn[J].Br J Haematol,2017,176(4):651-660. [39] JENNEWEIN M F,ABU-RAYA B,JIANG Y,et al.Transfer of maternal immunity and programming of the newborn immune system[J].Semin Immunopathol,2017,39(6):605-613. [40] MARTINEZ D R,FONG Y,LI S H,et al.Fc characteristics mediate selective placental transfer of IgG in HIV-infected women[J].Cell,2019,178(1): 190-201.e11. [41] JENNEWEIN M F,GOLDFARB I,DOLATSHAHI S,et al.Fc glycan-mediated regulation of placental antibody transfer[J].Cell,2019,178(1):202-215.e14. [42] YASUDA H,OHTO H,NOLLET K E,et al.Hemolytic disease of the fetus and newborn with late-onset Anemia due to anti-M: a case report and review of the Japanese literature[J].Transfus Med Rev,2014,28(1): 1-6. [43] KAUR G,BASU S,KAUR P,et al.Clinically significant anti M antibodies——a report of two cases[J].Transfus Apher Sci,2012,47(3):259-261. [44] ZWIERS C,KOELEWIJN J M,VERMIJ L,et al.ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy[J].Transfusion,2018,58(7):1611-1617. [45] Society for Maternal-Fetal Medicine (SMFM),BERRY S M,STONE J,et al.Fetal blood sampling[J].Am J Obstet Gynecol,2013,209(3):170-180. [46] SALOMON L J,SOTIRIADIS A,WULFF C B,et al.Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis[J].Ultrasound Obstet Gynecol,2019,54(4):442-451. [47] LO Y M,CORBETTA N,CHAMBERLAIN P F,et al.Presence of fetal DNA in maternal plasma and serum[J].Lancet,1997,350(9076):485-487. [48] LO Y M,TEIN M S,LAU T K,et al.Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis[J].Am J Hum Genet,1998,62(4):768-775. [49] SMID M,GALBIATI S,VASSALLO A,et al.No evidence of fetal DNA persistence in maternal plasma after pregnancy[J].Hum Genet,2003,112(5/6):617-618. [50] YU S C,LEE S W,JIANG P,et al.High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J].Clin Chem,2013,59(8):1228-1237. [51] FINNING K,MARTIN P,SUMMERS J,et al.Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study[J].BMJ,2008,336(7648):816-818. [52] QURESHI H,MASSEY E,KIRWAN D,et al.BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J].Transfus Med,2014,24(1):8-20. [53] CHITTY L S,FINNING K,WADE A,et al.Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study[J].BMJ,2014,349:g5243. [54] DE HAAS M,THURIK F F,VAN DER PLOEG C P,et al.Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands[J].BMJ,2016,355: i5789. [55] CLAUSEN F B,STEFFENSEN R,CHRISTIANSEN M,et al.Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women-2 years of screening experience from Denmark[J].Prenat Diagn,2014,34(10):1000-1005. [56] CLAUSEN F B,RIENECK K,KROG G R,et al.Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis[J].Methods Mol Biol,2019,1885:347-359. [57] WIKMAN A T,TIBLAD E,KARLSSON A,et al.Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy[J].Obstet Gynecol,2012,120(2 Pt 1):227-234. [58] BENACHI A,DELAHAYE S,LETICEE N,et al.Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study[J].Eur J Obstet Gynecol Reprod Biol,2012,162(1):28-32. [59] TEITELBAUM L,METCALFE A,CLARKE G,et al.Costs and benefits of non-invasive fetal RhD determination[J].Ultrasound Obstet Gynecol,2015,45(1):84-88. [60] SIN S T K,JIANG P Y,DENG J E,et al.Identification and characterization of extrachromosomal circular DNA in maternal plasma[J].PNAS,2020,117(3):1658-1665. [61] ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy[J]. Obstet Gynecol, 2018. 131(3):e82-e90. [62] 贺坤华,林裕翔,徐银霞,等.罕见IgG抗PP1PK致新生儿溶血病1例[J].南京医科大学学报(自然科学版),2021,41(2):310-312. [63] SARIHI R,AHMADNEJAD M,MOHAMMADI S,et al.Hemolytic disease of the fetus and newborn caused by anti-Hr0 in a 27-year-old female with Dc- phenotype: a case report[J].Transfus Apher Sci,2021,60(1):102913. [64] 李志强. RhD抗原阴性孕产妇血液安全管理专家共识[J].中国输血杂志,2017,30(10): 1085-1091. [65] 肖军,郑飞天,陈柄澔,等.O型孕产妇IgG抗体效价与胎儿新生儿溶血病关系的meta分析[J].中国输血杂志,2020,33(9):925-928. [66] Green-top guideline no.65: the management of women with red cell antibodies during pregnancy[J].Obstet Gynecol,2014,16(3):224. [67] WHITE J,QURESHI H,MASSEY E,et al.Guideline for blood grouping and red cell antibody testing in pregnancy[J].Transfus Med,2016,26(4):246-263. [68] SLOOTWEG Y M,LINDENBURG I T,KOELEWIJN J M,et al.Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management[J].Am J Obstet Gynecol,2018,219(4):393.e1-393.e8. [69] VAN WAMELEN D J,KLUMPER F J,DE HAAS M,et al.Obstetric history and antibody titer in estimating severity of kell alloimmunization in pregnancy[J].Obstet Gynecol,2007,109(5):1093-1098. [70] SLOOTWEG Y M,LINDENBURG I T,KOELEWIJN J M,et al.Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management[J].Am J Obstet Gynecol,2018,219(4):393.e1-393.e8. [71] 马印图,王更银,李烛,等.微柱凝胶技术检测血型抗体IgG亚型的应用评价[J].临床血液学杂志(输血与检验),2019,32(2):106-108. [72] 马印图,王更银,李玉秋,等.微柱凝胶技术检测血型抗体IgG亚型试验方法的建立[J].临床血液学杂志(输血与检验),2018,31(4):253-256. [73] TONG T N,BURKE-MURPHY E,SAKAC D,et al.Optimal conditions for the performance of a monocyte monolayer assay[J].Transfusion,2016,56(11):2680-2690. [74] TONG T N,CEN S,BRANCH D R.The monocyte monolayer assay: past,present and future[J].Transfus Med Rev,2019,33(1):24-28. [75] OEPKES D,VAN KAMP I L,SIMON M J,et al.Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization[J].Am J Obstet Gynecol,2001,184(5):1015-1020. [76] LUCAS G F,HADLEY A G,NANCE S J,et al.Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test[J].Transfusion,1993,33(6):484-487. [77] Society for Maternal-Fetal Medicine (SMFM),ORG P,MARI G,et al.Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for Anemia—diagnosis and management[J].Am J Obstet Gynecol,2015,212(6):697-710. [78] MARI G.Noninvasive diagnosis by Doppler ultrasonography of fetal Anemia due to maternal red-cell alloimmunization[J].Obstet Gynecol Surv,2000,55(6):341-342. |